Pharmacological management of cancer pain

Journal of Opioid Management

Volumn 5, Issue 2, 2009, Pages 89-96

  Montagnini, Marcos L ^a   Zaleon, Carolyn R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cancer; Opioids; Pain

Indexed keywords

17 METHYLNALTREXONE; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; BISACODYL; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CODEINE; CORTICOSTEROID; FENTANYL; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; LIDOCAINE; METHADONE; MORPHINE; NALOXONE; NEOSTIGMINE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PAROXETINE; PREGABALIN; SENNA EXTRACT; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADJUVANT THERAPY; ANALGESIA; ATAXIA; BONE PAIN; CANCER PAIN; CANCER PATIENT; CONFUSION; CONSTIPATION; CUSHINGOID SYNDROME; DISEASE COURSE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; ECCHYMOSIS; EDEMA; FATIGUE; FUNCTIONAL STATUS; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HUMAN; HYPERALGESIA; HYPERCALCEMIA; HYPERGLYCEMIA; INTRAOCULAR HYPERTENSION; LIVER TOXICITY; MENTAL DISEASE; MYOCLONUS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; NYSTAGMUS; OPIATE ADDICTION; OROPHARYNX CANDIDIASIS; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PEPTIC ULCER; POSTHERPETIC NEURALGIA; PRURITUS; QT PROLONGATION; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; STOMACH ULCER; THROMBOCYTE AGGREGATION INHIBITION; URINE RETENTION; VOMITING; WEIGHT GAIN; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

EID: 65749105197     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2009.0010     Document Type: Review

References (70)

1. World Health Organization: Cancer Pain Relief, 2nd ed. Geneva: WHO, 1996.
2. Grond S, Zech D, Diefenbach C, et al.: Prevalence and pattern of symptoms in patients with cancer pain: A prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage. 1994; 9(6): 372-382.
3. Levy MH, Samuel TA: Management of Cancer Pain. Semin Oncol. 2005; 32: 179-193.
4. Agency for Health Care Policy and Research, Acute Pain Management Panel: Acute Pain Management. Operative or Medical Procedures and Trauma. Clinical Practice Guideline. Washington, DC: US Department of Health and Human Services, 1992.
5. Fortner BV, Demarco G, Irving G, et al.: Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage. 2003; 25(1): 9-18.
6. O'Mahony S, Goulet J, Kornblith A, et al.: Desire for hastened death, cancer pain and depression: Report of a longitudinal observational study. J Pain Symptom Manage. 2005; 29(5): 446-457.
7. De Pinto M, Dunbar PJ, Edwards WT: Pain management. Anesthesiol Clin. 2006; 24(1): 19-37.
8. Caraceni A, Portenoy RK: An international survey of cancer pain characteristics and syndromes. IASP task force on cancer pain. International Association for the Study of Pain. Pain. 1999; 82(3): 263-274.
9. Jacox A, Carr DB, Payne R, et al.: AHCPR Clinical Practice Guideline. Management of Cancer Pain. Rockville, MD: Public Health Service Agency for Health Care Policy and Research, 1996; 10: 96-0592.
10. Zech DF, Grond S, Lynch J, et al.: Validation of World Health Organization guidelines for cancer pain relief: A 10-year prospective study. Pain. 1995; 63(1): 65-76.
11. Cleary JF: The pharmacologic management of cancer pain. J Palliat Med. 2007; 10 (6): 1369-1394.
12. Dworkin RH, O'Connor AB, Backonja M, et al.: Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 2007; 132: 237-251.
13. American Pain Society: Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 5th ed. Glenview, IL: American Pain Society, 2003.
14. Levy MH, Samuel TA: Management of cancer pain. Semin Oncol. 2005; 32(2): 179-193.
15. Forman WB: Opioid analgesic drugs in the elderly. Clin Geriatr Med. 1996; 12(3): 489-500.
16. Cherny NI, Portenoy RK: The management of cancer pain. CA Cancer J Clin. 1994; 44(5): 263-303.
17. Poyhia R, Seppala R, Olkkola KT, et al.: The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992; 33(6): 617-621.
18. Sloan PA, Barkin RL: Oxymorphone and oxymorphone extended release: A pharmacotherapeutic review. J Opioid Manage. 2008; 4(3): 131-144.
19. Chamberlin KW, Cottle M, Neville R, et al.: Oral oxymorphone for pain management. Ann Pharmacother. 2007; 41: 1144-1152.
20. Payne R, Chandler S, Einhaus M: Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs. 1995; 6 (Suppl 3): 50-53.
21. Donner B, Zenz M, Tryba M, et al.: Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain. Pain. 1996; 64(3): 527-534.
22. Basskin LE. Oral transmucosal fentanyl citrate: A new dosage form for breakthrough malignant pain. Am J Pain Manage. 1999; 9:129-138.
23. Messina J, Darwisit M, Fine PG: Fentanyl buccal tablet. Drugs Today. 2008; 440): 41-54.
24. Krantz MJ, Martin J, Stimmel B, et al.: QTc interval screening in methadone treatment. Ann Int Med. 2009: 150(6).
25. Chhabra S, Bull J: Methadone. Am J Hospice Palliat Med. 2008; 25: 146-50.
26. Lewis KS, Han NH: Tramadol: A new centrally acting analgesic. Am J Health Syst Pharm. 1997; 54(6): 643-652.
27. Wilder-Smith CH, Schimke J, Osterwalder B, et al.: Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 1994; 59(2): 141-146.
28. Petzke F, Radbruch L, Sabatowski R, et al.: Slow release tramadol for treatment of chronic malignant pain - An open multicenter trial. Support Care Cancer. 2001; 9(1): 48-54.
29. Cherny N, Ripamonti C, Pereira J, et al.: Strategies to manage the adverse effects of oral morphine: An evidence-based report. J Clin Oncol. 2001; 19(9): 2542-2554.
30. Payne R, Mathias SD, Pasta DJ, et al.: Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998; 16(4): 1588-1593.
31. Montagnini ML, Moat ME: Non-pain symptom management in palliative care. Clin Fam Practice. 2004; 6(2): 395-422.
32. Skykes NP: An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996-110(2): 135-144.
33. Rubiales AS, Hernansanz S, Gutierrez C, et al.: Neostigmine for refractory constipation in advanced cancer patients. J Pain Symptom Manage. 2006; 32(3): 204-205.
34. Thomas J, Karver S, Cooney GA, et al.: Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008; 358: 2332-2343.
35. Lawlor PG: The panorama of opioid-related cognitive dysfunction in patients with cancer: A critical literature appraisal. Cancer. 2002; 94(6): 1836-1856.
36. Cox JM, Pappagallo M: Modafinil: A gift to portmanteau. Am J Hosp Palliat Care. 2001; 18(6): 408-410.
37. McNeill JA, Sherwood GD, Starck PL. The hidden error of mismanaged pain: A systems approach. J Pain Symptom Manage. 2004; 28(1): 47-58.
38. Zylicz Z, Smits C, Krajnik M: Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage. 1998; 16(2): 121-124.
39. Larijani GE, Goldberg ME, Rogers KH: Treatment of opioid-induced pruritus with ondansentron: Report of four patients. Pharmacotherapy. 1996; 16(5): 958-960.
40. MacDonald N, Der L, Allan S, et al.: Opioid hyperexcitability: The application of alternate opoid therapy. Pain 1993; 53(3): 353-355.
41. Passik SD, Kirsh KL: Managing pain in patients with aberrant drug-taking behaviors. J Supportive Oncol. 2005; 3: 83-86.
42. Prater CD, Aylstra RG, Miller KE: Successful pain management for the recovering addicted patient. J Clin Psych. 2002; 4: 125-131.
43. Abranowicz, M: Treatment guidelines from the Medical Letter. Drugs for pain. Med Lett. 2004; 2(23): 47-54.
44. McDonald AA, Portenoy RK: How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. J Support Oncol. 2006; 4: 43-52.
45. Caraceni A, Zecca E, Bonezzi C, et al.: Gabapentin for neuropathic pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004; 22(14): 2909-2917.
46. Shin SW, Eisenach JC: Peripheral nerve injury sensitizes the response to visceral distention but not its inhibition by the antidepressant milnacipram. Anesthesiology. 2004; 100(3): 671-675.
47. Galler BS, Rowtbotham MC, Perander J: Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehical topical patch: Results of an enriched enrollment study. Pain. 1999; 80: 533-538.
48. Ellison N, Loprinzi CL, Kugler J, et al.: Phase 111 placebo controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol. 1997; 15(8): 2974-2980.
49. Watson CP, Tyler KL, Bickers DR, et al.: A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993; 15(3): 510-526.
50. Twycross R: The risks and benefits of corticosteroids in advanced cancer. Drug Safety. 1994; 11(3): 163-178.
51. Sorensen S, Helweg-Larsen S, Mouridsen H, et al.: Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: A randomized controlled trial. Eur J Cancer. 1994; 30(1): 22-27.
52. Ellershaw JE, Kelly MJ: Corticosteroids and peptic ulceration. Palliat Med. 1994; 8(4): 313-319.
53. Glover D, Lipton A, Keller A, et al.: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: A dose seeking study. Cancer. 1994; 74(11): 2949-2955.
54. Hortobagyi GN, Theriault RL, Porter L, et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996; 335(24): 1785-1791.
55. Berenson JR, Rosen LS, Howell A, et al.: Zoledronic acid reduces skeletat-related events in patients with osteolytic metastases. Cancer. 2001; 91(7): 1191-1200.
56. Lipton A, Small E, Saad F, et al.: The new biphosphonate Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate. Cancer Invest. 2002; 20 (Suppl 2); 45-54.
57. Rosen LS, Gordon D, Kaminski M, et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double blind, comparative trial. Cancer J. 2001; 7(5): 377-387.
58. Mystakidou K, Befon S, Hondros K, et al.: Continuous subcutaneous administration of high-dose salmon calcitonin in bone metastasis: Pain control and beta-endorphin plasma levels. J Pain Symptom Manage. 1999; 18(5): 323-330.
59. Hindley AC, Hill EB, Leyland MJ, et al.: A double-blind controlled trial of salmon calcitonin in pain due to malignancy. Cancer Chemother Pharmacol. 1982; 9(2): 71-74.
60. Roth A, Kolaric K: Analgesic activity of calcitonin in patient with painful osteolytic metastases of breast cancer. Results of a controlled randomized study. Oncology. 1986; 43(5): 283-287.
61. Martinez MJ, Roque M, Alonso-Coelho P, et al.: Calcitonin for metastatic bone pain. Cochrane Database Syst Rev. 2003; (3): CD003223.
62. Robinson RG, Preston DF, Schiefelbein M, et al.: Strontium-89 therapy for palliation of pain due to osseous metastases. JAMA. 1995; 274(5): 420-424.
63. Serafini AN, Houston SJ, Resche I, et al.: Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind, placebo controlled clinical trial. J Clin Oncol. 1998; 16(4): 1574-1581.
64. Lam MG, de Klerk JM, van Rijk PP: 186-Re-HEDp for metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging. 2004; 31 (Suppl 1): S162-S170.
65. Finlay IG, Mason MD, Shelley M: Radioisotopes for the palliation of metastatic bone cancer: A systematic review. Lancet Oncol. 2005; 6: 392-400.
66. Eide K, Stubhaugh A, Oye I, et al.: Continuous subcutaneous administration of N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of postherpetic neuralgia. Pain. 1995; 61(2): 221-228.
67. Stannard CF, Porter GE: Ketamine hydrochloride in the treatment of phantom limb pain. Pain. 1993; 54(2): 227-230.
68. Persson J, Axelsson G, Hallin RG, et al.: Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. Pain. 1995; 60(2): 217-222.
69. Lauretti GR, Lima IC, Reis MP, et al.: Oral ketamine and transdermal nitroglycerine as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology. 1999; 90(6): 1528-1533.
70. Kannan TR, Saxena A, Bhatnagar S, et al.: Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage. 2002; 23(1): 60-65.